SPICA THERAPEUTICS
ActiveSummary
SPICA THERAPEUTICS has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.2m and a net result of -€2.7m. Its solvency ranks better than 80% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Overview
Official details
Source: KBO- Status
- Active since 26-08-2024 Normal situation
- Registered office
- 106 active companies are registered at this address 17 started in the 12 months before. Source: KBO register, as of 1 November 2026.
- Activity
- Research and development on biotechnology NACE 72101and 4 others
- Joint committees
- 116 Paritair Comité voor de scheikundige nijverheid
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment unit
- 2.365.709.046 2600 Antwerpen, since 26-08-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 25-11-2024
Board and ownership
- BIOSKILLSDirector · since 27-05-2025 · permanent representative VAN HEUSDEN Jimmy Arnold Viviane
- DEBORA DUMONT MANAGEMENT COMPANYDirector · since 27-05-2025 · permanent representative DUMONT Debora Catharina Dominique
- Impala ConsultingDirector · since 27-05-2025 · permanent representative DEMOULIN Alexander Bharmal
- BIOQUBE FACTORY FUND I42.2%· score 962025 annual accounts of BIOQUBE FACTORY FUND I
- Flanders Future Techfund17.71%· score 892025 annual accounts of Flanders Future Techfund
- QBIC III FUND7.08%· score 962025 annual accounts of QBIC III FUND
- Holdings
- Shares in 1 company OncoSpear ApS
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.1%
- Gross margin
- -€1.0m
- Loss
- €2.7m
- Equity
- €6.2m
- Total assets
- €7.5m
- Employees on 31-12-2025
- 3
Score breakdownraises risk2 changes of registered office in 24 monthsLoss of €2.7m (financial year 2025)lowers riskSector: Scientific research and development (NACE 72)Size: total assets €7.5mShow the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small). It does better than 85% of them on solvency, 63% on liquidity and 11% on profitability.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Searched, nothing found (1)
Key points
Recent changes
- · Gazette deed Resignation: Impala Consulting Comm.V (director)Appointments: ALTHUARDE LIFE SCIENCES (director) and Abbey Consulting (director)
- · Gazette deed Resignation: Impala Consulting Comm.V (director)Appointment: ALTHUARDE LIFE SCIENCES (director) · Permanent representative: Roderick Verhelst
- · Gazette deed Resignation: Triangulate GmbH (ceo bestuurder)
Comparable companies
These companies have the same main activity as SPICA THERAPEUTICS: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €3.7m and €26m, founded between 2022 and 2025.
| Company | Total assets | Gross margin |
|---|---|---|
| SPICA THERAPEUTICS Antwerpen | €7.5m | -€1.0m |
| Tanai Therapeutics Gent | €3.9m | -€0.5m |
| Aboleris Holdco Charleroi | €14.8m | -€5.8m |
| HepaVue Dx Waterloo | €3.7m | -€0.3m |
| BioWorks Westerlo | €25.7m | -€2.0m |
| CANCER STATE THERAPEUTICS Charleroi | €4.0m | -€0.1m |
| Smappee Group Harelbeke | €23.2m | €0.002m |
Key facts about SPICA THERAPEUTICS
- What is the company number of SPICA THERAPEUTICS?
- The company number of SPICA THERAPEUTICS is 1012.800.853. The VAT number is the same number with BE in front: BE 1012.800.853.
- Where is SPICA THERAPEUTICS based?
- The registered office is at Uitbreidingstraat 66, 2600 Antwerpen.Company details
- What does SPICA THERAPEUTICS do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of SPICA THERAPEUTICS?
- The legal form of SPICA THERAPEUTICS is Public limited company (NV).
- When was SPICA THERAPEUTICS founded?
- SPICA THERAPEUTICS was founded on 26-08-2024.
- Is SPICA THERAPEUTICS still active?
- Yes, SPICA THERAPEUTICS is an active enterprise in the KBO register.
- How many employees does SPICA THERAPEUTICS have?
- SPICA THERAPEUTICS had an average of 0.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does SPICA THERAPEUTICS fall under?
- In its 2025 annual accounts, SPICA THERAPEUTICS states joint committees 116 (Paritair Comité voor de scheikundige nijverheid) and 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of SPICA THERAPEUTICS?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.
- Is SPICA THERAPEUTICS profitable?
- In financial year 2025, SPICA THERAPEUTICS made a loss of €2.7m.
- Where can I find the annual accounts of SPICA THERAPEUTICS?
- SPICA THERAPEUTICS filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
See how customers, suppliers and banks see your own company and what to improve first.